Fast recovery with etanercept in patients affected by polymyalgia rheumatica and decompensated diabetes: A case-series study

Clinical Rheumatology

Volumn 28, Issue 1, 2009, Pages 89-92

  Corrao, Salvatore ^a   Pistone, Giovanni ^b   Scaglione, Rosario ^a   Colomba, Daniela ^a   Calvo, Luigi ^a   Licata, Giuseppe ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b National Relevance Hospital Trust Civico e Benfratelli G di Cristina M Ascoli   (Italy)

Author keywords

Biological therapy; Decompensated diabetes mellitus; Etanercept; Polymyalgia rheumatica; Steroid therapy

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INSULIN; ISOPHANE INSULIN; PREDNISONE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; PAIN ASSESSMENT; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; VISUAL ANALOG SCALE;

AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN G; INSULIN; MALE; POLYMYALGIA RHEUMATICA; PREDNISONE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 57049154885     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1026-6     Document Type: Article

References (23)

1. Cimmino MA, Zaccaria A (2000) Epidemiology of polymyalgia rheumatica. Clin Exp Rheumatol 18(suppl 20):S9-S11
2. Salvarani C, Macchioni P, Bioardi L (1997) Polymyalgia rheumatica. Lancet 350:43-47
3. Kyle V (1997) Polymyalgia reumatica. Prescribers' J 3:138-144
4. Chuang T, Hunder GG, Ilstrup DM, Kurland LT (1982) Polymyalgia rheumatica - A 10 year epidemiological and clinical study. Ann Intern Med 97:672-680
5. Cimmino MA, Moggiana G, Montecucco C, Caporali R, Accardo S (1994) Long term treatment of polymyalgia rheumatica with deflazacort. Ann Rheum Dis 53:331-333
6. Gran JT (1999) Current therapy of polymyalgia rheumatica [editorial]. Scand J Rheumatol 28:269-272
7. Salvarani C, Cantini F, Boiardi L, Hunder GG (2002) Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347:261-271
8. Salvarani C, Boiardi L, Mantovani V, Ranzi A, Cantini F, Olivieri I et al (1999) HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: Correlation with disease severity. Ann Rheum Dis 58:303-308
9. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106-114
10. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J et al (2002) A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46:1309-1318
11. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C et al (2004) Prednisone plus methotrexate for polymyalgia rheumatica. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 141:493-500
12. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P et al (2007) Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: A randomized trial. Ann Intern Med 46(9):631-639
13. The Oxford Centre for Evidence-based Medicine Levels of Evidence (2007) http://www.pdptoolkit.co.uk/Files/ebm/indexes/guide%20to%20ebm.htm Accessed July 2 2007
14. Kalke S, Mukerjee D, Dasgupta B (2000) A study of the health assessment questionnaire to evaluate functional status in polymyalgia rheumatica. Rheumatology 39(8):883-885
15. Salvarani C, Cantini F, Niccoli L, Catanoso MG, Macchioni P, Pulsatelli L et al (2003) Treatment of refractory polymyalgia rheumatica with infliximab: A pilot study. J Rheumatol 30(4):760-763
16. Migliore A, Massafra U, Carloni E, Padalino C, Martin Martin S, Lasaracina F et al (2005) TNF-alpha blockade induce clinical remission in patients affected by polymyalgia rheumatica associated to diabetes mellitus and/or osteoporosis: A seven cases report. Eur Rev Med Pharmacol Sci 9(6):373-378
17. Tam LS, Tomlinson B, Chu TT, Li TK Li EK (2007) Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 26(9):1495-1498
18. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J (2006) Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol 24(1):83-86
19. Yazdani-Biuki B, Mueller T, Brezinschek HP, Hermann J, Graninger W, Wascher TC (2006) Relapse of diabetes after interruption of chronic administration of anti-tumor necrosis factor-alpha antibody infliximab: a case observation. Diabetes Care 29(7):1712-1713
20. Adachi T, Toishi T, Takashima E, Hara H (2006) Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro. Biol Pharm Bull 29(10):2095-2098
21. Iyama S, Okamoto T, Sato T, Yamauchi N, Sato Y, Sasaki K et al (2001) Treatment of murine collagen-induced arthritis by ex vivo extracellular superoxide dismutase gene transfer. Arthritis Rheum 44(9):2160-2167
22. Adachi T, Inoue M, Hara H, Maehata E, Suzuki S (2004) Relationship of plasma extracellular-superoxide dismutase level with insulin resistance in type 2 diabetic patients. J Endocrinol 181(3):413-417
23. Bernstein LE, Berry J, Kim S, Canavan B, Grinspoon SK (2006) Effects of etanercept in patients with the metabolic syndrome. Arch Intern Med 166(8):902-908